Lymphoid Malignancies, Lymphoproliferative Disorders
Conditions
Brief summary
The purpose of this study is to determine if treatment with HQK-1004 and valganciclovir will result in complete or partial responses in patients with EBV-positive lymphoid malignancies or lymphoproliferative disorders.
Interventions
DRUGHQK-1004
1,000 mg/kg/day administered IV 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
DRUGValganciclovir (may substitute with ganciclovir)
900 mg BID oral for 21 days (Days 1-21 of each 21 day cycle). If the subject cannot tolerate or absorb valganciclovir, ganciclovir my be administered instead at 5 mg/kg intravenously BID until the subject can tolerate and absorb valganciclovir.
Sponsors
HemaQuest Pharmaceuticals Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed lymphoid malignancy or lymphoproliferative disorder with EBV detected by either immunohistochemistry or in situ hybridization. Pathology can be assessed on either a current or previous biopsy. All disease stages are eligible * Disease that is refractory or relapsed after at least one prior standard therapeutic regimen, which includes biologic agents (e.g., monoclonal antibodies), chemotherapy or chemoradiotherapy regimens. Prior therapy may include high dose chemotherapy and stem cell rescue or bone marrow transplantation * Bidimensionally measurable disease by computerized tomography (CT) or magnetic resonance imaging (MRI; patients with sensitivity to contrast or for tumor types that are less accurately measured by CT) scan or physical measurement (cutaneous lesions only) with at least 1 lesion ≥ 10 mm in the greatest diameter. PET-CT should be used at baseline for patients with Hodgkin's Disease (HD) or diffuse large B-cell lymphoma (DLBCL). * Absolute neutrophil count ≥ 500/mm3 and platelet count ≥ 50,000/mm3 * Bilirubin ≤ 2.0 times upper limit of normal (ULN) with the exception of patients with Gilbert's syndrome (bilirubin ≤ 3.5 times ULN allowed), and both AST and ALT ≤ 3 times ULN * Serum creatinine ≤ 2.0 mg/dL
Exclusion criteria
* Patients who have not recovered from previous treatment with chemotherapy * Patients who have been treated with biologic agents within two weeks prior to first dose of HQK-1004 * Uncontrolled ischemic heart disease or uncontrolled congestive heart failure, or myocardial infarction within the past 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate | Days 21, 42, 84 and 126 |
Secondary
| Measure | Time frame |
|---|---|
| Safety and tolerability as measured by adverse events, physical exams, ECG, and laboratory evaluations | through end of treatment (up to Day 126) and 30 days post last dose |
| Overall and progression-free survival | through end of treatment (up to Day 126), then every 8 weeks for 1 year post last dose |
Countries
United States
Outcome results
None listed